Clinical research study to evaluate the effectiveness and safety of a potential oral medication for subjects with metastatic castration resistant prostate cancer


Last updated date
Study Location
The Clatterbridge Cancer Centre - Liverpool
Liverpool, , L7 8YA, United Kingdom

Study Website

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Who can take part in the study?

You may be able to join the TALAPRO-2 study if you meet the following criteria:

  • you have a diagnosis of metastatic castration-resistant prostate cancer
  • you are 18 years of age or older
  • you are willing to provide saliva, blood and tumor tissue samples for genetic testing
  • you are otherwise in reasonably good health

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

You will not be able to take part in the study if you have received:

  • systemic cancer treatment (treatment that enters the bloodstream to reach cells all over the body), not including androgen deprivation therapy and first-generation anti-androgens, since your metastatic castration-resistant prostate cancer diagnosis
  • treatment with enzalutamide, apalutamide or darolutamide (and certain other therapies used in the treatment of prostate cancer that your doctor will be able to check for you)
  • treatment with platinum-based chemotherapy within 6 months (from the last dose)

There are other requirements for participation in the study.  The study doctor will be able to explain these to you.


For Patients: Please visit the study website for more information

All other inquiries: Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

mCRPCClinical research study to evaluate the effectiveness and safety of a potential oral medication for subjects with metastatic castration resistant prostate cancer
  1. Liverpool,
  2. Anchorage, Alaska
  3. Chandler, Arizona
  4. Gilbert, Arizona
  5. Gilbert, Arizona
  6. Gilbert, Arizona
  7. Mesa, Arizona
  8. Mesa, Arizona
  9. Scottsdale, Arizona
  10. Tucson, Arizona
  11. Tucson, Arizona
  12. Beverly Hills, California
  13. Chula Vista, California
  14. Chula Vista, California
  15. Glendale, California
  16. Greenbrae, California
  17. La Mesa, California
  18. Loma Linda, California
  19. Loma Linda, California
  20. Loma Linda, California
  21. Long Beach, California
  22. Los Angeles, California
  23. Orange, California
  24. Palo Alto, California
  25. Rancho Mirage, California
  26. Rancho Mirage, California
  27. San Diego, California
  28. San Diego, California
  29. San Diego, California
  30. Aurora, Colorado
  31. Aurora, Colorado
  32. Aurora, Colorado
  33. Aurora, Colorado
  34. Aurora, Colorado
  35. Denver, Colorado
  36. Danbury, Connecticut
  37. New Milford, Connecticut
  38. Norwalk, Connecticut
  39. Altamonte Springs, Florida
  40. Brandon, Florida
  41. Celebration, Florida
  42. Clearwater, Florida
  43. Daytona Beach, Florida
  44. Fort Myers, Florida
  45. Gainesville, Florida
  46. Kissimmee, Florida
  47. Lakeland, Florida
  48. Largo, Florida
  49. Lecanto, Florida
  50. New Port Richey, Florida
  51. Ocala, Florida
  52. Orange City, Florida
  53. Orlando, Florida
  54. Orlando, Florida
  55. Orlando, Florida
  56. Saint Petersburg, Florida
  57. Spring Hill, Florida
  58. Tampa, Florida
  59. Tavares, Florida
  60. The Villages, Florida
  61. Vero Beach, Florida
  62. Wellington, Florida
  63. West Palm Beach, Florida
  64. Winter Park, Florida
  65. Athens, Georgia
  66. Atlanta, Georgia
  67. Atlanta, Georgia
  68. Atlanta, Georgia
  69. Atlanta, Georgia
  70. Fayetteville, Georgia
  71. Newnan, Georgia
  72. Newnan, Georgia
  73. Chicago, Illinois
  74. Chicago, Illinois
  75. Chicago, Illinois
  76. Chicago, Illinois
  77. Hinsdale, Illinois
  78. Hinsdale, Illinois
  79. Zion, Illinois
  80. Jeffersonville, Indiana
  81. Iowa City, Iowa
  82. Fairway, Kansas
  83. Westwood, Kansas
  84. Wichita, Kansas
  85. Wichita, Kansas
  86. Louisville, Kentucky
  87. New Orleans, Louisiana
  88. Baltimore, Maryland
  89. Troy, Michigan
  90. Saint Louis, Missouri
  91. Billings, Montana
  92. Billings, Montana
  93. Omaha, Nebraska
  94. Omaha, Nebraska
  95. Omaha, Nebraska
  96. Omaha, Nebraska
  97. Belleville, New Jersey
  98. Voorhees, New Jersey
  99. Albuquerque, New Mexico
  100. Farmington, New Mexico
  101. Bronx, New York
  102. Poughkeepsie, New York
  103. Syracuse, New York
  104. Cincinnati, Ohio
  105. Middleburg Heights, Ohio
  106. Oklahoma City, Oklahoma
  107. Clackamas, Oregon
  108. Clackamas, Oregon
  109. Hillsboro, Oregon
  110. Newberg, Oregon
  111. Portland, Oregon
  112. Portland, Oregon
  113. Portland, Oregon
  114. Springfield, Oregon
  115. Altoona, Pennsylvania
  116. Bethel Park, Pennsylvania
  117. Greensburg, Pennsylvania
  118. Lancaster, Pennsylvania
  119. Monroeville, Pennsylvania
  120. Philadelphia, Pennsylvania
  121. Pittsburgh, Pennsylvania
  122. Pittsburgh, Pennsylvania
  123. Pittsburgh, Pennsylvania
  124. Seneca, Pennsylvania
  125. Uniontown, Pennsylvania
  126. Washington, Pennsylvania
  127. Myrtle Beach, South Carolina
  128. Chattanooga, Tennessee
  129. Chattanooga, Tennessee
  130. Cleveland, Tennessee
  131. Harrogate, Tennessee
  132. Jefferson City, Tennessee
  133. Knoxville, Tennessee
  134. Knoxville, Tennessee
  135. Morristown, Tennessee
  136. Nashville, Tennessee
  137. Nashville, Tennessee
  138. Nashville, Tennessee
  139. El Paso, Texas
  140. Houston, Texas
  141. Temple, Texas
  142. Farmington, Utah
  143. Salt Lake City, Utah
  144. Salt Lake City, Utah
  145. Salt Lake City, Utah
  146. South Jordan, Utah
  147. Fairfax, Virginia
  148. Fairfax, Virginia
  149. Seattle, Washington
  150. Seattle, Washington
  151. Madison, Wisconsin
  152. Madison, Wisconsin
  153. Pergamino, Buenos Aires
  154. Rosario, Santa FE
  155. Caba,
  156. Caba,
  157. Caba,
  158. Cordoba,
  159. Cordoba,
  160. Camperdown, New South Wales
  161. Darlinghurst, New South Wales
  162. Port Macquarie, New South Wales
  163. Auchenflower, Queensland
  164. Auchenflower, Queensland
  165. Brisbane, Queensland
  166. Chermside, Queensland
  167. South Brisbane, Queensland
  168. South Brisbane, Queensland
  169. Southport, Queensland
  170. Melbourne, Victoria
  171. North Melbourne, Victoria
  172. Brasschaat,
  173. Gent,
  174. Gent,
  175. Kortrijk,
  176. Ottignies,
  177. Yvoir,
  178. Rio de Janeiro, RJ
  179. Rio de Janeiro, RJ
  180. Rio de Janeiro, RJ
  181. Rio de Janeiro, RJ
  182. Ijui, RS
  183. Lajeado, RS
  184. Porto Alegre, RS
  185. Porto Alegre, RS
  186. Barretos, SP
  187. Santo Andre, SP
  188. Santo Andre, SP
  189. Sao Paulo, SP
  190. Sao Paulo, SP
  191. Sao Paulo, SP
  192. Sao Paulo, SP
  193. São Paulo, SP
  194. Calgary, Alberta
  195. Ottawa, Ontario
  196. Chicoutimi, Quebec
  197. Montreal, Quebec
  198. Montreal, Quebec
  199. Sherbrooke, Quebec
  200. Santiago, Metropolitana
  201. Santiago, Metropolitana
  202. Temuco, Region DE LA Araucania
  203. Temuco, Region DE LA Araucania
  204. Vina del Mar, Valparaiso
  205. Vina del Mar, Valparaiso
  206. Hefei, Anhui
  207. Beiijng, Beijing
  208. Beijing, Beijing
  209. Beijing, Beijing
  210. Fuzhou, Fujian
  211. Xiamen, Fujian
  212. Wuhan, Hubei
  213. Wuhan, Hubei
  214. Nanjing, Jiangsu
  215. Suzhou, Jiangsu
  216. Wuxi, Jiangsu
  217. Nanchang, Jiangxi
  218. Shanghai, Shanghai
  219. Shanghai, Shanghai
  220. Shanghai, Shanghai
  221. Xi'an, Shanxi
  222. Chengdu, Sichuan
  223. Kunming, Yunnan
  224. Hangzhou, Zhejiang
  225. Hangzhou, Zhejiang
  226. Ningbo, Zhejiang
  227. Chongqing,
  228. Shanghai,
  229. Shanghai,
  230. Shanghai,
  231. Tianjin,
  232. Hradec Kralove,
  233. Ostrava-Poruba,
  234. Pardubice,
  235. Pardubice,
  236. Praha 10,
  237. Usti nad Labem,
  238. Helsinki,
  239. Helsinki,
  240. Helsinki,
  241. Kempele,
  242. Kuopio,
  243. Kuopio,
  244. Oulu,
  245. Tampere,
  246. Turku,
  247. Bayonne,
  248. Bayonne,
  249. Bordeaux Cedex,
  250. Bordeaux,
  251. LA ROCHE SUR YON cedex 9,
  252. Le Mans,
  253. Le Mans,
  254. Lyon CEDEX 08,
  255. Montpellier cedex 5,
  256. Paris Cedex 15,
  257. Paris,
  258. Paris,
  259. Strasbourg,
  260. Strasbourg,
  261. Suresnes Cedex,
  262. Suresnes,
  263. VILLEJUIF cedex,
  264. Erlangen, Bayern
  265. Duesseldorf,
  266. Erlangen,
  267. Hamburg,
  268. Heidelberg,
  269. Kirchheim,
  270. Muenster,
  271. Nuertingen,
  272. Ravensburg,
  273. Reutlingen,
  274. Weiden,
  275. Budapest,
  276. Budapest,
  277. Budapest,
  278. Budapest,
  279. Debrecen,
  280. Debrecen,
  281. Pecs,
  282. Haifa,
  283. Haifa,
  284. Jerusalem,
  285. Petah Tikva,
  286. Tel Aviv,
  287. Bologna, BO
  288. Cremona, CR
  289. Meldola, FC
  290. Terni, TN
  291. Trento, TN
  292. Orbassano, TO
  293. Brescia,
  294. Napoli,
  295. Napoli,
  296. Nagoya, Aichi
  297. Hirosaki, Aomori
  298. Kashiwa, Chiba
  299. Matsuyama, Ehime
  300. Kure, Hiroshima
  301. Sapporo, Hokkaido
  302. Sapporo, Hokkaido
  303. Kanazawa, Ishikawa
  304. Yokohama, Kanagawa
  305. Yokosuka, Kanagawa
  306. Osaka-shi, Osaka
  307. Osakasayama, Osaka
  308. Suita, Osaka
  309. Hamamatsu, Shizuoka
  310. Meguro-ku, Tokyo
  311. Shinjuku-ku, Tokyo
  312. Chiba,
  313. Fukuoka,
  314. Kagoshima,
  315. Kumamoto,
  316. Tokushima,
  317. Yamagata,
  318. Yamagata,
  319. Goyang-si, Gyeonggi-do
  320. Goyang-si, Gyeonggi-do
  321. Busan,
  322. Daegu,
  323. Seoul,
  324. Seoul,
  325. Seoul,
  326. Seoul,
  327. Seoul,
  328. Seoul,
  329. Seoul,
  330. Seoul,
  331. Seoul,
  332. Tauranga, BAY OF Plenty
  333. Christchurch, Canterbury
  334. Hamilton, Waikato
  335. Auckland,
  336. Auckland,
  337. Gralum,
  338. Gralum,
  339. Lorenskog,
  340. Norbyhagen,
  341. Oslo,
  342. Oslo,
  343. Trondheim,
  344. Trondheim,
  345. Arequipa,
  346. Lima,
  347. Lima,
  348. Lima,
  349. Lima,
  350. Brzozow,
  351. Gdynia,
  352. Konin,
  353. Otwock,
  354. Warszawa,
  355. Braga,
  356. Evora,
  357. Lisboa,
  358. Lisboa,
  359. Porto,
  360. Porto,
  361. Port Elizabeth, Eastern CAPE
  362. Johannesburg, Gauteng
  363. Johannesburg, Gauteng
  364. Johannesburg, Gauteng
  365. Cape Town, Western CAPE
  366. George, Western CAPE
  367. Kraaifontein, Cape Town, Western CAPE
  368. Santiago de Compostela, A Coruna
  369. Elche, Alicante
  370. L'Hospitalet de Llobregat, Barcelona
  371. L'Hospitalet de Llobregat, Barcelona
  372. Sabadell, Barcelona
  373. El Palmar, Murcia
  374. Barcelona,
  375. Barcelona,
  376. Madrid,
  377. Madrid,
  378. Madrid,
  379. Madrid,
  380. Goteborg,
  381. Stockholm,
  382. Umeå,
  383. Umeå,
  384. Plymouth, Devon
  385. Bebington, Wirral
  386. Cornwall,
  387. Glasgow,
  388. London,
  389. London,
  390. London,
  391. Oxford,
18 Years+
Advanced Information
Descriptive Information
Brief Title  ICMJE Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Brief Summary This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Detailed Description Part 1 is an open-label, non-randomized, safety and PK run-in study designed to confirm the starting dose of talazoparib in combination with enzalutamide through assessment of target safety events and PK at select sites. Part 2 is a randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus enzalutamide in patients with mCRPC.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
To assess radiographic PFS in men with mCRPC (with no systemic treatments initiated after documentation of mCRCP) treated with talazoparib and enzalutamide vs. placebo plus enzalutamide
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Primary Purpose: Treatment
Condition  ICMJE mCRPC
Intervention  ICMJE
  • Drug: Talazoparib with enzalutamide
    Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
  • Drug: Placebo with enzalutamide
    Placebo plus enzalutamide 160 mg/day
Study Arms  ICMJE
  • Experimental: Combination arm
    Talazoparib plus enzalutamide
    Intervention: Drug: Talazoparib with enzalutamide
  • Active Comparator: Monotherapy arm
    Ezalutamide plus placebo
    Intervention: Drug: Placebo with enzalutamide
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: September 3, 2019)
Original Estimated Enrollment  ICMJE
 (submitted: January 3, 2018)
Estimated Study Completion Date  ICMJE November 25, 2024
Estimated Primary Completion Date August 22, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Histologically or cytologically confirmed adenocarcinoma of the prostate withoutsmall cell or signet cell features

Asymptomatic or mildly symptomatic metastatic castration resistant prostate cancer (mCRPC) (score on BPI-SF Question #3 must be < 4).

For enrollment into Part 2 only (optional in Part 1): assessment of DDR mutation status

Consent to a saliva sample collection for a germline comparator unless prohibited by local regulations or ethics committee decision (optional for patients in Part 1).

Surgically or medically castrated, with serum testosterone ? 50 ng/dL (? 1.73 nmol/L) at screening.

Metastatic disease in bone documented on bone scan or in soft tissue documented on CT/MRI scan.

Progressive disease at study entry in the setting of medical or surgical castration as defined by 1 or more of the following 3 criteria:

  • Prostate specific antigen (PSA) progression defined by a minimum of 2 rising PSA values from 3 consecutive assessments with an interval of at least 7 days between assessments..
  • Soft tissue disease progression as defined by RECIST 1.1.
  • Bone disease progression defined by Prostate Cancer Working Group 3 (PCWG3) with 2 or more new metastatic bone lesions on a whole body radionuclide bone scan.

Ongoing bisphosphonate or denosumab use prior to Day 1 (Part 1) or randomization (Part 2) is allowed but not mandatory.

Eastern Cooperative Oncology Group (ECOG) performance status ? 1.

Life expectancy ? 12 months as assessed by the investigator.

Able to swallow the study drug and have no known intolerance to study drugs or excipients.

Must agree to use a condom when having sex with a partner from the time of the first dose of study drug through 4 months after last dose of study treatment. Must also agree for female partner of childbearing potential to use an additional highly effective form of contraception from the time of the first dose of study treatment through 4 months after last dose of study treatment when having sex with a non pregnant female partner of childbearing potential.

Must agree not to donate sperm from the first dose of study drug to 4 months after the last dose of study drug.

Evidence of a personally signed and dated informed consent document (and molecular prescreening consent if appropriate) indicating that the patient [or a legally acceptable representative/legal guardian] has been informed of all pertinent aspects of the study.

Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

Any prior systemic cancer treatment initiated in in the non metastatic CRPC and mCRPC disease state.

Patients whose only evidence of metastasis is adenopathy below the aortic bifurcation.

Prior treatment with second-generation androgen receptor inhibitors (enzalutamide, apalutamide, and darolutamide), a PARP inhibitor, cyclophosphamide, or mitoxantrone for prostate cancer.

Prior treatment with platinum-based chemotherapy within 6 months (from the last dose) prior to Day 1 (Part 1) or randomization (Part 2), or any history of disease progression on platinum-based therapy within 6 months (from the last dose).

Treatment with cytotoxic chemotherapy, biologic therapy including sipuleucel T, or radionuclide therapy received in the castration-sensitive prostate cancer is NOT exclusionary if discontinued in the 28 days prior to Day 1 (Part 1) or randomization (Part 2).

Treatment with any investigational agent within 4 weeks before Day 1 (Part 1) or randomization (Part 2).

Prior treatment with opioids for pain related to either primary prostate cancer or metastasis within 28 days prior to Day 1 (Part 1) or randomization (Part 2).

Current use of potent P-gp inhibitors within 7 days prior to Day 1 (Part 1) or randomization (Part 2).

Major surgery (as defined by the investigator) within 2 weeks before Day 1 (Part 1) or randomization (Part 2), or palliative localized radiation therapy within 3 weeks before randomization (Part 2).

Clinically significant cardiovascular disease

Significant renal dysfunction as defined by any of the following laboratory abnormalities:

? Renal: eGFR < 30 mL/min/1.73 m2 by the MDRD equation (available via

Patients enrolled in Part 1 only: Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2) at screening.

Significant hepatic dysfunction as defined by any of the following laboratory abnormalities on screening labs:

  • Total serum bilirubin >1.5 times the upper limit of normal (ULN) (>3 × ULN for patients with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation).
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times ULN (>5 × ULN if liver function abnormalities are due to hepatic metastasis).
  • Albumin <2.8 g/dL

Absolute neutrophil count < 1500/µL, platelets < 100,000/µL, or hemoglobin < 9 g/dL (may not have received growth factors or blood transfusions within 14 days before obtaining the hematology values at screening).

Known or suspected brain metastasis or active leptomeningeal disease.

Symptomatic or impending spinal cord compression or cauda equina syndrome.

Any history of myelodysplastic syndrome, acute myeloid leukemia, or prior malignancy except any of the following:

  • Carcinoma in situ or non melanoma skin cancer
  • Any prior malignancies ?3 years before randomization with no subsequent evidence of recurrence or progression regardless of the stage.
  • Stage 0 or Stage 1 cancer <3 years before randomization that has a remote probability of recurrence or progression in the opinion of the investigator

Gastrointestinal disorder affecting absorption.

Fertile male subjects who are unwilling or unable to use highly effective methods of contraception for the duration of the study and for 4 months after the last dose of investigational product.

Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.

Other acute or chronic medical (concurrent disease, infection, or comorbidity) or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that interferes with ability to participate in the study, may increase the risk associated with study participation or investigational product administration, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke, significant brain trauma). Also, history of loss of consciousness or transient ischemic attack within 12 months of randomization (Part 2).

Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Gender Based Eligibility:Yes
Gender Eligibility Description:Men at least 18 years of age. For Japan, at least 20 years of age.
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Argentina,   Australia,   Belgium,   Brazil,   Canada,   Chile,   China,   Czechia,   Finland,   France,   Germany,   Hungary,   Israel,   Italy,   Japan,   Korea, Republic of,   New Zealand,   Norway,   Peru,   Poland,   Portugal,   South Africa,   Spain,   Sweden,   United Kingdom,   United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT03395197
Other Study ID Numbers  ICMJE C3441021
2017-003295-31 ( EudraCT Number )
TALAPRO-2 ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at:….
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Astellas Pharma Inc
Investigators  ICMJE
Study Director:Pfizer Call CenterPfizer
PRS Account Pfizer
Verification Date October 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP